hospitalization. This increases the costs associated with surgery and results in overall economic burden on society. 11, 12 Also the POPF associated morbidity frequently delays the timely delivery of adjuvant therapies reducing overall survival. 13, 14 The International Study Group of Pancreatic Fistula (ISGPF) formed an objective definition of POPF as fluid output of any measureable volume via an operatively placed drain after post-operative day 3 with amylase level greater than 3 times the upper normal serum value and graded it as grades A, B, and C according to the complication-specific severity. 15, 16 Grade B and C fistulas are collectively referred to clinically relevant POPF (CR-POPF).
As a result of the high incidence of POPF, routine practice among surgeons has been to place a drain after PD. Prospective randomized trial by Buren et al has provided level 1 data against elimination of drains in all cases of PD. 17 Optimal timing of removal of drain has been a subject of debate. Prolonged drainage is associated with increased complications, duration of hospital stay and resource utilization. 18 Prospective study by Kawai et al. reported lower rates of abdominal complications following early drain removal. 19 Randomized study by Bassi et al. suggested reduced risk of CR-POPF, if postoperative day (POD) 1 drain fluid amylase ≤5000 U/l and hence early drain removal in these patients. 18 However significant controversy persists about the dynamic post-operative changes in drain output volume and amylase concentration and their correlation with CR-POPF. This controversy over the drain management and the significant impact of POPF on overall surgical outcome has made prediction of CR-POPF an important topic of investigation. 20, 21 Currently no consensus exists regarding whether drain fluid amylase concentration or volume of drain output are important in predicting CR-POPF and whether they are more predictive on any particular post-operative day. Such a predictor would be useful in deciding timing of drain removal and identifying patients who require close monitoring.
The fistula risk score (FRS) developed by Callery et al, is a four-factor score which takes into account pancreatic duct diameter, gland texture, pathology and intraoperative blood loss. 22, 23 FRS classifies patients into negligible (score 0), low (score 1-2), moderate (score 3-6) or high (score 7-10) risk categories for developing POPF. Both FRS and postoperative drain amylase levels on different postoperative days have been analyzed in past as predictors of CR-POPF. However, currently there is no clear consensus regarding the ideal predictor. Hence, the present study sought to assess the utility of POD-3 drain amylase level (POD3DA) as a predictor of CR-POPF in comparison with FRS in patients undergoing PD.
METHODS

consecutive patients who underwent PD at
Department of Surgical-Gastroenterology and Liver transplant, Bangalore medical college and research institute, Bangalore, between March 2014 to May 2018 were included. This includes patients undergoing surgery for both malignant and benign pathology. All patients underwent classical Whipple procedure.
Data collection
Current study is a retrospective analysis of data extracted from review of a prospectively maintained electronic database and patient medical records. For all patients data obtained on patient demographics, clinical history, past medical history, family and social history, physical findings, body mass index (BMI), diagnostic tests, detailed operative data, complications, postoperative interventions and outcome and histopathological data. Pancreatic duct diameter determined at the line of resection by preoperative computed tomography and magnetic resonance cholangiopancreatography. Intraoperative data included pancreatic gland texture (hard/firm or soft), estimated blood loss. Histopathologically specimen were segregated into two categories on the basis of whether the pathology associated with hard/firm pancreatic parenchyma (pancreatic adenocarcinoma and chronic pancreatitis) or normal/soft parenchyma (ampullary adenocarcinoma, duodenal carcinoma, distal cholangiocarcinoma, pancreatic head neuroendocrine tumours or cystic neoplasm or other lesions). FRS was calculated for each patient as described by Callery et al and patients are dichotomized into negligible or low risk and moderate or high risk category. 22, 23 Outcome data included total length of stay in an ICU which includes any readmission to ICU due to complications and total length of postoperative hospital stay which includes rehospitalisation for complications pertaining to surgery. Drain fluid amylase level estimated on POD-3 for all patients and POPF diagnosed according to ISGPF definition. Postoperative complications recorded and graded according to International Study Group of Pancreatic Surgery (ISGPS) classification and POPF grade reviewed during followup. 24 
Operative procedure and perioperative management
All surgeries performed under single surgical gastroenterology unit and operative steps of PD followed as previously described. [25] [26] [27] Pancreatic remnant anastomosis done using double layer duct to mucosa technique with either jejunum (pancreaticojejunostomy (PJ)) or stomach (pancreaticogastrostomy) according to surgeon's preference. Two non-suction drains (28-32 Fr, ADK) were routinely placed at pancreatic and biliary anastomosis site. No somatostatin analogues were used perioperatively. Patients were extubated on POD-0 or 1 as per anaesthetist's decision. All patients were kept under ICU observation for first 48 hours after surgery and then transferred to general ward or HDU according to their clinical condition. Drain fluid volumes were recorded daily and constant criteria followed for drain removal i.e. drain output of less than 50 ml over 24 hour with no POPF and no other contraindication for drain removal (e.g. bile or chyle leak or purulent discharge). In patients with POPF drain removal was done when minimal daily output (<30 ml) for 3 consecutive days or repeat drain amylase negative for POPF with no other contraindications. Patients with grade B or C POPF managed as per clinical requirement with provisions of supportive care, antibiotics, percutaneous drainage, and angio-embolisation for pseudo aneurysm and surgical exploration.
Outcome measures
POPF was defined and classified by the ISGPF definition i.e. drain fluid amylase level ≥3 times the upper limit of normal serum amylase level for each specific institution on or after POD3. 17 The upper normal limit of serum amylase at our institute is 100 IU/l, hence drain amylase level ≥300 IU/l on POD3 considered as POPF. Patients with grade A POPF currently termed as Biochemical leak (BL) were clinically non-significant requiring no additional treatment or no deviation from a normal postoperative course. Grade B POPF patients required additional treatment, intensive care and prolonged hospital stay. Grade C POPF patients often had a life threatening event or morbid postoperative period. They frequently required interventional radiologic procedure like angioembolisation for post-pancreatectomy haemorrhage or dialysis or ventillatory support or relaparotomy. Grade B and C patients collectively referred to as clinically relevant POPF (CR-POPF). Postoperatively FRS was calculated for each patient using the variables described by Callery et al. 24 Patients are stratified into negligible risk (FRS-0), low risk (FRS-1 to 2), intermediate risk (FRS-3 to 6), and high risk (FRS-7 to 10). All patients were then dichotomized into either negligible/low risk category or intermediate/ high risk category for predicting CR-POPF.
Statistical analysis
Statistical analysis was performed using Statistical Package for the Social Sciences 16.0 for Windows (SPSS, Inc). For continuous variables, descriptive statistics calculated and reported as mean ± standard deviation (SD). To compare continuous variables, the Mann-Whitney U-test was used. Fisher's exact test used to compare categorical variables. The independent sample t test (unpaired t test) was used to evaluate differences in means of continuous variables. Receiver operating characteristic (ROC) curve analysis was done to identify optimum threshold level of POD3 drain amylase for predicting CR-POPF. The area under the ROC curve (AUC) is a measure of diagnostic accuracy of a test. 28 AUC of >0.75 considered to have high diagnostic accuracy indicating more than 75% of cases with the condition of interest are classified correctly. 29 FRS calculated for all 57 patients stratified them into four different risk categories. 24 Among them 2 (3.5%) were negligible risk (FRS=0), 22 (38.6%) were low risk (FRS=1-2), 30 (52.6%) were moderate risk (FRS= 3-6) and 3 (5.2%) were high risk (FRS= 7-10) group. Mean FRS of the cohort was 3.36 (SD-1.702, median 3, range 0-7). Mean FRS of patients who had CR-POPF was 4.1 (SD 1.6) as opposed to 3.05 (SD 1.63) in no CR-POPF group and the difference of mean was significant (p=0.039). None of 2 negligible risk category patients developed CR-POPF, while 4/22 (18.2%), 12/30 (40%) and 2/3 (66.6%) patients of low, moderate and high risk categories respectively developed a CR-POPF. When patients are dichotomized into two groups i.e. negligible/low group vs. moderate/high group, the incidence of CR-POPF was significantly lower in the negligible/low group (16.6%) compared to the moderate/high group (42.4%) which was statistically significant (p=0.047). The sensitivity and specificity of moderate/high FRS for predicting CR-POPF was 77.8% and 51.2% respectively with a negative predictive value of 83.3%. Similar analyses of POD3 drain fluid amylase undertaken for all patients. The mean POD3DA was 916 IU/l in CR-POPF group and 447 IU/l in patients with no CR-POPF and the difference of mean between the two group was significant (p=0.042). In Figure 1 the distribution of PoD3 drain amylase in patients who developed CR-POPF and those who did not is plotted (box plot). An analysis by ROC was performed on the cohort who had CR-POPF, which revealed a significant correlation between POD3 drain amylase levels and CR-POPF (AUC = 0.868, 95% CI 0.78-0.92). The optimal threshold for POD3 drain amylase level for predicting CR-POPF was >486 IU/l with sensitivity of 94.4% and specificity of 79.5%. This value was corrected to 500 IU/l (5 times of upper limit of normal serum amylase at our institute, normal range 60-100 IU/l) for clinical convenience and subsequently validated (Fishers exact test). A total of 23 patients had a POD3DA of ≥500 IU/l, out of which 15 (65.2%) developed CR-POPF and only 3 (9.6%) out of (p<0.001). A PoD3 drain amylase level ≥500 IU/l was strongly associated with the occurrence of CR-POPF (sensitivity 83%, specificity 79%; p<0.001) with positive predictive value of 65.2% and negative predictive value of 91.2%. The sensitivity, specificity and the AUC of the ROC curve are presented in Table 2 The comparison of the AUC for the ROC curve between the two predictive tests (POD3DA ≥500 IU/l vs. dichotomized FRS-moderate/high) revealed a statistically significant difference in predicting the development of CR-POPF ( Figure 2 ). The AUC for POD3DA ≥500 IU/l was 0.868 and the AUC for FRS-moderate/high risk patients was 0.692. Hence POD3DA ≥500 IU/l was found to be statistically superior in predicting CR-POPF (p=0.028). When both POD3DA ≥500 IU/l and moderate/ high-FRS are combined, the sensitivity decreased to 67% for predicting CR-POPF and it did not prove to be superior to either of the individual test (Table 2) . 
DISCUSSION
CR-POPF continues to be the major cause of morbidity post PD. The ability to make a reliable prediction of postoperative CR-POPF may enable surgeons to individualize the postoperative management strategy and minimize the morbidity associated with CR-POPF. In spite of some published evidence against routine placement of intraoperative drains after PD, majority of institutions follow a routine placement of drain. 30, 31 Few studies have advocated omitting drains in patients having negligible or low risk of POPF by FRS as well as early removal of drains in patients with POD1DA below a predesignated cut-off. [32] [33] [34] This study is an effort to externally validate the effectiveness of FRS as a predictive test of CR-POPF. Also this study is the first to document POD3 drain amylase level (POD3DA <5 times of upper normal serum range) as an objective marker to predict patients with low risk for CR-POPF for whom early drain removal and enhanced postoperative recovery may be predicted. International Surgery Journal | January 2020 | Vol 7 | Issue 1 Page 232 from institute to institute and it was felt that a more standardized value of PoD3 drain amylase level might be of value in predicting the presence or absence of CR-POPF.
The incidence of clinically relevant POPF in the current cohort is 31%, which is within expected range when compared to the reported incidence of CR-POPF in literature. 36, 37 The 7% rate of clinically significant PPH in this cohort is also within expected range as found in literature. 38 The mean FRS of 3.36, this cohort is comparable to 3.54 as reported by Callery et al, in the multi-institutional study to validate FRS indicating the baseline risk of the study cohort is comparable to the study cohort used to validate FRS. 39
CONCLUSION
Both POD3DA ≥500 IU/l and moderate/high FRS are effective in predicting the development of CR-POPF in the current study with sensitivity of 94% and 78% respectively. However the ROC curve showed the superiority of POD3DA ≥500 IU/l over moderate/high FRS in predicting CR-POPF (AUC 0.868 vs. 0.692, AUC diff. 0.175, p=0.028). The difference in specificity between the two groups is also significant (79.5% vs. 51.2%, p<0.05). This indicates POD3DA <500 IU/l is more accurate in ruling out CR-POPF than negligible/low FRS group. When both moderate/high FRS and POD3DA ≥500 IU/l were combined, it achieved a high specificity (87.2%) as opposed to low sensitivity (66.7%). Out of 24 patients with negligible/low FRS, 13 (54%) developed POPF and 4 (16.6%) developed CR-POPF which can not be ignored. Hence the present study recommends against non-placement of intraoperative drain in negligible/low FRS category patients. However drains should be removed as early as on postoperative day 3 if the POD3DA <500 IU/l in these patients thereby avoiding the potential morbidity associated with prolonged drainage. The high negative predictive value of POD3DA more than equal to 5 times of normal serum upper range (≥500 IU/l) in association with negligible/low FRS risk category might be highly precise in identifying patients at low risk for CR-POPF and associated morbidity. Such patients therefore can be put on enhanced recovery protocol with early drain removal and early discharge, thus saving health care resources.
Limitations
This study is limited by its retrospective nature and nonrandomized analysis in a small cohort of patient operated at a single institute. With regards to data pertaining to gland texture no standardized criteria was applied and subjective variation has to be accounted. Although this analysis of prospectively maintained data gives a nonambiguous positive correlation, this is a preliminary investigation and further validation of the result is necessary and is currently on-going.
